University of Guelph researchers report adipocyte FGF21 signalling connects protein restriction and metabolic cellular ageing

Researchers reported that adipocyte FGF21 signalling acts as a cellular link connecting dietary protein restriction to metabolic cellular ageing, providing a specific target for healthspan-mimicking therapies.

In a study published in The Journal of Physiology, researchers Holloway CM and Holloway SW from the University of Guelph reported that adipocyte FGF21 signalling connects protein restriction and metabolic cellular ageing.

The study details how the metabolic benefits of dietary protein restriction are mediated via tissue-specific FGF21 signaling pathways in fat cells, which influences downstream cellular ageing processes.

Dietary interventions like protein restriction have shown potential to extend healthspan, but translating these dietary regimens into clinical therapies requires identifying the precise cellular targets.

Pinpointing adipocyte-specific FGF21 signalling as the critical mediator opens up possibilities to design therapeutics that replicate these benefits without requiring caloric or protein restriction.

This mechanism supports therapeutic programs aiming to modulate FGF21 for age-related metabolic disorders.

While preclinical, the validation of tissue-specific (adipocyte) pathways suggests that localized or selective FGF21 therapies could optimize therapeutic efficacy while limiting systemic off-target effects.

Preclinical studies evaluating whether pharmacological activation of adipocyte-specific FGF21 signalling can replicate the longevity and metabolic improvements of protein restriction.